Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 11/20 | 0.41 |
| ▸ | NEK2 | P51955 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | MPL | P40238 | 1/20 | 0.37 |
| ▸ | IDH2 | P48735 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15022112 | 0.87 | ALDH1A1 (0.50) | KDM4EALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL3667418 | 0.83 | ALDH1A1 (0.53) | KDM4EALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL27794105 | 0.81 | POLB (0.53) | KDM4EALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL12082581 | 0.77 | EIF2AK4 (0.55) | KDM4EALDH1A1HSD17B10HPGDLRRK2 | |
| SCHEMBL12184995 | 0.74 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL15022110 | 0.74 | KDM4E (0.50) | KDM4EALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL5348100 | 0.73 | POLB (0.47) | ALDH1A1NOTUM | |
| SCHEMBL31241515 | 0.71 | KDM4E (0.46) | KDM4EALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL31334623 | 0.71 | SMN1; SMN2 (0.48) | KDM4EALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL19441162 | 0.71 | NOTUM (0.50) | KDM4EALDH1A1HSD17B10KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517873-B2 | Substituted pyrimidodiazepines | HOFFMAN-LA ROCHE INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234255-A1 | SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | KDM4E 1150/4885ALDH1A1 1365/4885HSD17B10 1673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.